Abstract
To evaluate the combined effect of granisetron and methylprednisolone against acute emesis induced by cytotoxic agents, we investigated the clinical response and the urinary excretion of 5-HIAA in 85 patients with ovarian cancer who received the same anticancer chemotherapeutic regimen in a prospective randomized trial. Each patient received one of three different regimens (granisetron alone, methylprednisolone plus granisetron, and metoclopramide alone). The combination therapy of granisetron and methylprednisolone is effective for preventing acute emesis induced by cytotoxic chemotherapy.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Granisetron / administration & dosage
-
Granisetron / therapeutic use*
-
Humans
-
Hydroxyindoleacetic Acid / urine
-
Methylprednisolone / administration & dosage
-
Methylprednisolone / therapeutic use*
-
Metoclopramide / therapeutic use
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Vomiting / chemically induced
-
Vomiting / prevention & control*
Substances
-
Antineoplastic Agents
-
Hydroxyindoleacetic Acid
-
Metoclopramide
-
Granisetron
-
Methylprednisolone